Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Liye Chen has been awarded a Versus Arthritis five-year career development fellowship to identify and validate new T cell therapeutic targets in ankylosing spondylitis (AS).

AS is a painful and progressive form of inflammatory arthritis, affecting around 200,000 people in the UK. The disease causes inflammation in the spine and other joints, leading to pain, stiffness, and fatigue.

Although treatment for AS has greatly improved in the past decade, a definitive cure has not yet been found and many patients suffer persistent symptoms or unacceptable side effects from current therapies.

AS has a strong genetic basis, with over 100 genetic variations linked to the condition. Through bioinformatics integration of genetic data and gene expression profiles of T cells from blood and joint fluid from patients with AS, the innovative programme of research will allow Dr Chen to identify novel T cell regulators in AS which are potential therapeutic targets.

Dr Chen says: “It’s very exciting to be able to look at AS through different lenses and bring such cutting-edge technologies to the table. The integration of multiple datasets (GWAS, eQTL and RNA sequencing of patient-derived T cells) and functional screen of identified genes using disease relevant cellular assays will allow us to identify genes that contribute to AS pathogenesis much faster than currently possible.”

Once the novel AS T cell regulators have been identified and validated in cellular assays, Dr Chen will focus on the most promising and novel regulators for their functional mechanisms and therapeutic potentials.

“I’m very grateful to Versus Arthritis for granting me the opportunity to contribute to such an important field or research, aiding their aims of finding a cure for major forms of arthritis and helping thousands of patients worldwide.” concludes Dr Chen.

Funded by

Versus Arthritis logo

Similar stories

Furniss Group paper wins journal award

Editors at the Journal of Hand Surgery have recognised the Furniss Group with an award for the best paper published in the Journal in 2022. The Editor’s Award recognises research with scientific importance, outstanding study stringency, and a high academic standard.

NIHR Fellowships awarded to NDORMS researchers

Congratulations to Eileen Morrow and Mae Chester-Jones who have received NIHR Doctoral Fellowships

ORUK Early Career Research Fellowship awarded to NDORMS researcher

Congratulations to Jack Tu who has been awarded an Orthopaedic Research UK Early Career Research Fellowship to explore the cause of knee pain after total knee replacement.

OCTRU - delivering answers to important clinical questions

The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report

Unhelpful thoughts about fracture symptoms hinder recovery

The importance of mindsets and feelings about fracture symptoms have been shown to be a key factor in recovery of musculoskeletal conditions.

Fat tissues can play a protective role against inflammation in the intestine

A new study in The EMBO Journal has revealed how fat tissues might provide a protective role in intestinal inflammation opening new lines of research into the treatment of inflammatory bowel diseases.